Navigation Links
PAR in Biological Technology

Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine

WOODCLIFF LAKE, N.J., Feb. 25 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX ) today announced that its development partner, Immtech Pharmaceuticals, Inc. (Amex: IMM ) has cho...

Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products

Pafuramidine on Clinical Hold Loramyc(R) Completes Patient Enrollment Ahead of Schedule Zensana(TM) Reformulation Complete, Resubmission on Target WOODCLIFF LAKE, N.J., Dec. 28 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX ) today pro...

Novavax Reports Second Quarter 2009 Financial Results

...compared to $33.9 million as of December 31, 2008. The company's short-term investments consist of investments in five auction rate securities with a par value of $8.1 million and a fair value of $6.0 million. In addition to the other than temporary impairment discussed above, during the second quarter ...

American Oriental Bioengineering Reports Second Quarter 2009 Financial Results

...OMMITMENTS EQUITY SHAREHOLDERS' EQUITY Preferred stock, $0.001 par value; 2,000,000 shares authorized; 1,000,000 shares issued and ...pectively 1,000 1,000 Common stock, $0.001 par value; 150,000,000 shares authorized; 78,301,439 and 78,249,264 s...

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

... 275.0 291.3 Total liabilities 2,652.2 2,635.2 Shareholders' equity: Common stock of 5p par value; 1,000 million shares authorized; and 560.3 million shares issued and outstanding (2008: 1,000 million shares authorized; and 560.2 ...

NxStage Reports Second Quarter 2009 Financial Results

...ingencies Stockholders' equity: Undesignated preferred stock: par value $0.001, 5,000,000 shares authorized; no shares issu...December 31, 2008 - - Common stock: par value $0.001, 100,000,000 shares authorized; 46,658,515 and ...

ERT Reports Second Quarter 2009 Results

...------ ------ Stockholders' equity: Preferred stock-$10.00 par value, 500,000 shares authorized, none issued and outstanding... - - Common stock-$.01 par value, 175,000,000 shares authorized, 59,950,257 and 59,985,4...

Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65.

...------- ------- Stockholders' equity: Common stock 201.8 201.8 Capital in excess of par value 137.8 133.0 Common stock in treasury (1,953.5) (1,935.3) Retained earnings ...

Essilor : First Half 2009 Revenue

...targeted acquisitions dynamic. In light of these factors, Essilor is confident in its ability to maintain first-half 2009 operating margin on a par with full-year 2008. Consolidated revenue for the first six months of 2009 EUR millions H1 2009 H1 2008 % Change % Change Con...

Vasogen Announces Second Quarter 2009 Results

... 1,288 1,242 Shareholders' equity: Share capital: Authorized: Unlimited common shares, without par value Issued and outstanding: 22,623,195 common shares (November 30, 2008 - 22,424,719) 365,730 365,677 ...

Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates

... Company has raised NOK 129 million (equivalent to USD 20 million) in gross proceeds through a private placement of 10,750,000 new shares, each with a par value of NOK 1.00 at a price of NOK 12.00 per share (the "Private Placement"). The Private Placement took place through a bookbuilding process ...

World Nanomedicine Market to Cross $160 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

....A., Elan Corporation Plc, Enzon Pharmaceuticals Inc., Life Technologies Corporation, Nanosphere Inc., Nektar Therapeutics, Novavax Inc., Oxonica Plc, par Pharmaceutical Companies Inc., Starpharma Holdings Limited, and Wyeth Pharmaceuticals Inc., among others. The report titled "Nanomedicine: A ...

Wyeth Announces Holder Right to Surrender Convertible Debentures

...terest payment on the Convertible Debentures. The current conversion rate of the Convertible Debentures is 16.7356 shares of Wyeth common stock, par value $0.33 1/3 per share (the "Common Stock"), payable at the option of the Company in cash and/or Common Stock, if any, per $1,000 aggregate princip...

Strativa's Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA

... products division of a wholly owned subsidiary of par Pharmaceutical Companies, Inc. (NYSE: PRX ), tod...aceuticals is the proprietary products division of par Pharmaceutical, Inc. Strativa is committed to deve...ease visit www.strativapharma.com . About par Pharmaceutical ...

Strativa's New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA

... products division of a wholly owned subsidiary of par Pharmaceutical Companies, Inc. (NYSE: PRX ), tod...aceuticals is the proprietary products division of par Pharmaceutical, Inc. Strativa is committed to deve...ease visit www.strativapharma.com . About par Pharmaceutical ...

Pharmacyclics Files Registration Statement for Rights Offering

.... The rights offering will be made through the distribution of non-transferable subscription rights to purchase shares of the Company's common stock, par value $0.0001 per share, at a subscription price to be determined. Assuming the rights offering is fully subscribed, the Company will receive gross p...

Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009

...Series A, convertible preferred stock, $0.001 par value, 5,000,000 shares authorized, none issu... -- Undesignated preferred stock, $.001 par value, 5,000,000 shares authorized, ... -- -- Common stock, $.001 par value, 100,000,000 shares authorized,23,...

MedClean Technologies, Inc. Announces Private Offer to Exchange Warrants

...rrants") for newly issued Common Stock Purchase Warrants, with a new lower exercise price, exercisable for a lesser number shares of our common stock, par value $0.0001 per share ("Common Stock"), and without a "cashless exercise" right (the "New Warrants"). The offer to exchange is being made upon the t...

Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results

...3,042 Total liabilities 476,900 447,326 65,466 Equity Simcere shareholders' equity Ordinary shares at par 9,624 9,353 1,369 Additional paid-in capital 1,505,252 1,404,555 205,558 Accumulated other c...

Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes

...odified Dutch Auction" tender offer (the "Exchange Offer") to increase the total consideration of its offer to exchange shares of its common stock, no par value (the "Common Stock"), and cash for an aggregate of up to $89.2 million principal amount of the following outstanding series of its convertible n...

China Biologic Products Announces Strong First Quarter 2009 Results

...49 -- COMMITMENTS AND CONTINGENCIES -- -- SHAREHOLDERS' EQUITY: Common stock, $0.0001 par value, 100,000,000 shares authorized, 21,434,942 shares issued and outstanding at March 31, 2009 and December 31, 2008 ...

China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results

...2 2,282,109 Stockholders' Equity: Preferred stock, $0.001 par value, 1,000,000 shares authorized, - 0 - shares issued...June 30, 2008 -- -- Common stock, $0.001 par value, 74,000,000 and 74,000,000 shares authorized, 30,...

Rodobo International, Inc. Reports Q2 and First Half of 2009

...ed and outstanding as of March 31, 2009 and September 30, 2008 12,976 12,976 Common stock, $0.001 par value, 1,604,278 shares authorized, 1,435,568 shares issued and outstanding as of March 31, 2009 and September 30, 2008 ...

PharmAthene Reports First Quarter 2009 Financial and Operational Results

... - 928,117 Total liabilities 37,149,763 37,427,831 Stockholders' equity: Common stock, $0.0001 par value; 100,000,000 shares authorized; 28,012,031 and 25,890,143 shares issued and outstanding at March 31, 2009 and Decemb...

Tiens Biotech Group (USA) Reports First Quarter Results

...Total liabilities 47,262,302 47,031,443 EQUITY: Shareholders' equity of the Company: Common stock, $0.001 par value, 250,000,000 shares authorized, 71,333,586 issued and outstanding, respectively 71,334 71,334 Pa...

Insmed Announces First Quarter 2009 Financial Results

... 2,217 Total liabilities 13,384 7,581 Stockholders' equity (deficit): Common stock; $.01 par value; authorized shares 500,000,000; issued and outstanding shares, 124,972,146 in 2009 and 122,494,010 in 2008 ...

Cell Therapeutics to Exchange up to $89.2 million of Its Outstanding Convertible Notes in a 'Modified Dutch Auction' Tender Offer

... CTIC) today announced that it has commenced a "Modified Dutch Auction" tender offer (the "Exchange Offer") to exchange shares of its common stock, no par value ("Common Stock"), and cash for an aggregate of $89.2 million principal amount for the following outstanding series of Convertible Notes (the "No...

Pharmasset Reports Fiscal Second Quarter 2009 Financial Results

... ---------- ---------- COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY Common Stock, $0.001 par value, 100,000,000 shares authorized, 28,111,991 and 23,340,498 shares issued and outstanding at March 31, 2009 (unaudited) and Se...

VIVUS Reports First Quarter 2009 Financial Results and Highlights

...DENSED CONSOLIDATED BALANCE SHEETS (in thousands, except par value amount) March 31 ...nts and contingencies Stockholders' equity: Common stock; $.001 par value; shares authorized 200,000; shares outstanding - 69,72...

American Oriental Bioengineering Reports First Quarter 2009 Financial Results

...78,194,557 EQUITY SHAREHOLDERS' EQUITY Preferred stock, $0.001 par value; 2,000,000 shares authorized; 1,000,000 shares issued and ...respectively 1,000 1,000 Common stock, $0.001 par value; 150,000,000 shares authorized; 78,291,735 and 78,249,264 s...

NxStage Reports First Quarter 2009 Financial Results

...anding, as of March 31, 2009 and December 31, 2008, respectively - - Common stock: par value $0.001, 100,000,000 shares authorized; 46,573,901 and 46,548,585 shares issued and outstanding, as of March ...

Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results

... (In thousands, except share and par value amounts) ...ockholders' equity: Preferred stock, $.001 par value, 10,000,000 shares authorized at ... - - Common stock, $.001 par value, 100,000,000 shares authorized at ...

Savient Pharmaceuticals Reports First Quarter 2009 Financial Results

...nd contingencies Stockholders' Equity: Preferred stock - $.01 par value 4,000,000 shares authorized; no shares issued ... - - Common stock - $.01 par value 150,000,000 shares authorized; 54,960,000 issued an...

Nektar Therapeutics Reports First Quarter 2009 Financial Results

...d stock - - Common stock 9 9 Capital in excess of par value 1,315,182 1,312,796 Accumulated other comprehensive income (loss) (20) 1,439 ...

Solutia Reports First Quarter 2009 Results

... 119 132 Commitments and Contingencies (Note 9) Shareholders' Equity: Common stock at $0.01 par value; (500,000,000 shares authorized, 94,518,392 and 94,392,772 shares issued in 2009 and 2008, respectively) ...

Senesco Technologies Reports Third Quarter Fiscal 2009 Financial Results

... STOCKHOLDERS' EQUITY: Preferred stock, $0.01 par value; authorized 5,000,000 shares, no shares... -- -- Common stock, $0.01 par value; authorized 100,000,000 shares, issued ... 195,112 183,751 Capital in excess of par 41,020,987 39,874,958 ...

BioMarin Announces First Quarter 2009 Financial Results

...56 2,946 Total liabilities 630,020 626,343 Stockholders' equity: Common stock, $0.001 par value: 250,000,000 shares authorized at December 31, 2008 and March 31, 2009; 99,868,145 and 99,977,953 shares issued ...

ERT Reports First Quarter 2009 Results

...4 27,995 Stockholders' equity: Preferred stock-$10.00 par value, 500,000 shares authorized, none issued and outstanding - - Common stock-$.01 par value, 175,000,000 shares authorized, 59,950,257 and 59,974,1...

Shire begins the year with a strong performance

... $M $M _________ _________ Shareholders' equity: Common stock of 5p par value; 1,000 million shares authorized; and 560.3 million shares issued and outstanding (2008: 1,000 million shares authorized; and 560.2 ...

Wyeth Announces Full Redemption of $2 Convertible Preferred Stock

...it will fully redeem all of its outstanding $2 Convertible Preferred Stock, par value $2.50 per share (the "Convertible Preferred Stock") effective on July...or a portion of, their Convertible Preferred Stock into Wyeth common stock, par value $0.33 1/3 per share (the "Common Stock"), by surrendering their share...
Other Tags
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
(Date:11/10/2014)... pods began appearing on U.S. store shelves in early ... ever since. The small packets can be tossed into ... a liquid or powder. The convenience, though, has come ... from researchers at Nationwide Children,s Hospital found that from ... of 17,230 children younger than 6 years of age ...
(Date:11/6/2014)... from a team of Florida State University biologists could ... adapt to and survive environmental swings such as droughts ... issue of the journal The Plant Cell , ... and proteins) is organized in a cell and how ... turned on and others are turned off. , "If ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Study finds laundry detergent pods, serious poisoning risk for children 2Maize analysis yields whole new world of genetic science 2
(Date:11/18/2014)... 18, 2014 A+ Secure Packaging, ... nutraceutical, dietary supplements and more, announced today that ... Good Manufacturing Practices (GMP) Registration for dietary supplements ... from NSF International verifies the A+ Secure Packaging ... compliance requirements of its clients by demonstrating the ...
(Date:11/18/2014)... 2014 Recently, Wigsbuy has introduced its ... are offered at greatly discounted prices now, up to 85% ... of human hair products, offering many real and synthetic hair ... global customers, Wigsbuy uses high quality materials to make its ... with the trend. , “We are offering a full ...
(Date:11/18/2014)... HealthDay Reporter , MONDAY, Nov. 17, ... not have significant heart-health benefits for older people, new ... than 14,000 Japanese people aged 60 to 85, found ... attacks and strokes between people who took aspirin and ... prevention with daily low-dose aspirin does not reduce the ...
(Date:11/18/2014)... By Dennis Thompson HealthDay ... doctor from Sierra Leone who became infected with Ebola in his ... Dr. Martin Salia had arrived Saturday at Nebraska Medical Center ... at a hospital in Sierra Leone,s capital city of Freetown. ... that have been ravaged by the Ebola outbreak that began last ...
(Date:11/17/2014)... 17, 2014 A Diet Doc ... throughout the country are turning back the clock on ... This is because the company has recently added their ... impressive collection of prescription and non-prescription diet products and ... Diet Doc’s best anti-aging human growth hormone ...
Breaking Medicine News(10 mins):Health News:A+ Secure Packaging, LLC Earns NSF International Good Manufacturing Practices (GMP) Registration for Dietary Supplements and Certification for Sport 2Health News:It Is The Most Wonderful Time To Buy Full Lace Wigs At Wigsbuy.com 2Health News:Daily Aspirin Fails to Help Older Hearts in Japanese Study 2Health News:Daily Aspirin Fails to Help Older Hearts in Japanese Study 3Health News:Doctor With Ebola Dies at Nebraska Hospital 2Health News:Best Anti-Aging Human Growth Hormone Therapy Safely and Naturally Restores Diet Doc Patients to More Youthful Levels 2Health News:Best Anti-Aging Human Growth Hormone Therapy Safely and Naturally Restores Diet Doc Patients to More Youthful Levels 3
Other Contents